Loading....
OUR SPEAKER
Aziz Nazha, MD is a hematologist/oncologist at the Cleveland Clinic, specializing in leukemias, MDS, AML, MPNs, myelofibrosis, CML, mastocytosis and CMML. Dr. Nazha received his medical degree from Tishreen University Faculty of Medicine in Lattakia, Syria and joined the Cleveland Clinic in 2016.
Dr. Nazha has presented numerous abstracts at the American Society of Hematology's annual meeting and has received numerous awards and recognition for his work in research and teaching.
WEBINAR DESCRIPTION
Dr. Nazha will discuss the treatment options available for MDS patients after hypomethylating agent (HMA) failure. Azacitidine and decitabine are the standard of care for MDS patients and more than 50% of patients respond favorably to the HMA, however some patients experience HMA failure. This webinar will discuss the therapy options available including ongoing clinical trials.
A Question and Answer session will be live as well!
Thank you for registering for Treating MDS after Hypomethylating Agent Failure on Tuesday, June 10, 2020 at 2:00pm EDT/1:00pm CDT.
You will receive an email with a registration confirmation
including the webinar link and a call-in phone # for those
participating via telephone. If you do not receive the link,
please check your Spam/Junk folders.
If you have not received a registration confirmation,
please email clark@aamds.org or call (800) 747-2820 x2 no later than 30 minutes
before the webinar is scheduled to begin.
If you are not able to join the webinar, an archived video will be available in 2 - 3 business days on the AAMDSIF website.